Research location

Villejuif

France

Published trials745

Site observations756

Linked trials published745

Page1 / 15

Research activity in Villejuif

France

CureCurrent currently publishes aggregate city-level research activity for this location: 745 trials and 756 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Villejuif

745 linked trials · page 1 of 15

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast CancerNCT07701941 · 2026-09-17 · 1 site observation

Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 LevelsNCT07360743 · 2026-08-21 · 1 site observation

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung CancerNCT07476287 · 2026-07-02 · 1 site observation

Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic TestsNCT07106632 · 2026-06-26 · 1 site observation

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerNCT07647328 · 2026-06-15 · 1 site observation

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseNCT07492641 · 2026-05-22 · 1 site observation

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerNCT07287098 · 2026-05-13 · 1 site observation

Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of CancerNCT07436312 · 2026-05-04 · 1 site observation

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)NCT07611110 · 2026-05-04 · 1 site observation

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)NCT07531095 · 2026-04-21 · 1 site observation

Phase 1 Study of PF-08046033 in Advanced Solid TumorsNCT07519655 · 2026-04-08 · 1 site observation

Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural MesotheliomaNCT07234058 · 2026-04-02 · 1 site observation

Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsNCT06907095 · 2026-03-16 · 1 site observation

Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt PlacementNCT07439939 · 2026-03-09 · 1 site observation

Evaluation of an Online Intervention to Educate Women at High Risk of Breast Cancer on How to Help Reduce Their Risk.NCT07120087 · 2026-02-19 · 1 site observation

Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity ManagementNCT07371585 · 2026-02-18 · 1 site observation

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate CancerNCT07258407 · 2026-01-30 · 1 site observation

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsNCT07195695 · 2026-01-16 · 1 site observation

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT07222566 · 2026-01-06 · 1 site observation

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336 · 2025-12-22 · 1 site observation

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate CancerNCT07225946 · 2025-12-19 · 1 site observation

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant RibociclibNCT07237256 · 2025-12-18 · 1 site observation

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung CancerNCT07226999 · 2025-12-09 · 1 site observation

Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously TreatedNCT06908993 · 2025-12-09 · 1 site observation

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPCNCT07226986 · 2025-12-05 · 1 site observation

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerNCT07213674 · 2025-11-28 · 1 site observation

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung CancerNCT07001618 · 2025-11-17 · 1 site observation

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful BiomarkersNCT07259226 · 2025-11-14 · 1 site observation

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyNCT07472517 · 2025-11-07 · 1 site observation

A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate CancerNCT07189403 · 2025-11-04 · 1 site observation

Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.NCT07192068 · 2025-10-30 · 1 site observation

Arm Swelling Occurence in Breast Cancer Patients With Nodal Radiotherapy: Impact of Informing Them of AI-predicted RiskNCT07187726 · 2025-10-07 · 1 site observation

A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast CancerNCT07159451 · 2025-10-06 · 1 site observation

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate CancerNCT07181161 · 2025-10-01 · 1 site observation

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)NCT07140016 · 2025-09-22 · 1 site observation

A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast CancerNCT06781996 · 2025-09-09 · 1 site observation

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT07164443 · 2025-09-02 · 1 site observation

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerNCT06982521 · 2025-08-26 · 1 site observation

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid TumorsNCT07169734 · 2025-08-26 · 1 site observation

Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid TumorsNCT07151040 · 2025-08-22 · 1 site observation

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]NCT07099898 · 2025-08-11 · 1 site observation

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationNCT06952803 · 2025-08-06 · 1 site observation

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid TumorsNCT07094113 · 2025-07-31 · 1 site observation

A Study of LY4175408 in Participants With Advanced CancerNCT07046923 · 2025-07-28 · 1 site observation

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid TumorsNCT07094204 · 2025-07-25 · 1 site observation

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)NCT06757634 · 2025-07-24 · 1 site observation

Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast CancerNCT06606730 · 2025-07-23 · 1 site observation

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)NCT07016230 · 2025-07-02 · 1 site observation

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate CancerNCT06990880 · 2025-06-12 · 1 site observation

Intermittent Androgen Deprivation Therapy in the Era of AR Pathway InhibitorsNCT05974774 · 2025-05-23 · 1 site observation

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.